AbbVie以1.4bn获得阿丽亚达治疗药物,获得老年痴呆症主要药物候选者和CNS交付技术。 AbbVie acquires Aliada Therapeutics for $1.4bn, gaining lead Alzheimer's drug candidate and CNS delivery technology.

AbbVie将用14亿美元购买Aliada治疗药物,这加强了其阿尔茨海默氏病和神经科学的重点。 AbbVie will acquire Aliada Therapeutics for $1.4 billion, enhancing its Alzheimer's disease and neuroscience focus. 这项收购包括阿里亚达的主要候选物,ALIA-1758,一种针对与阿尔茨海默病相关的特定粉样β形式的抗体. The acquisition includes Aliada's lead candidate, ALIA-1758, an antibody targeting a specific amyloid beta form related to Alzheimer's. 此外,AbbVie还有机会进入Aliada的配送平台,以准确提供CNS药物。 Additionally, AbbVie gains access to Aliada's Modular Delivery platform for precise CNS drug delivery. 该交易预计将于2024年第四季度完成,等待监管部门的批准. The deal is expected to close in Q4 2024, pending regulatory approvals.